Recent News

• 05.28.2025 - Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
• 05.28.2025 - Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
• 05.08.2025 - Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update
• 05.08.2025 - Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update
• 05.06.2025 - Compass Therapeutics to Participate in Upcoming May Investor Events
• 05.06.2025 - Compass Therapeutics to Participate in Upcoming May Investor Events
• 04.28.2025 - Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting
• 04.28.2025 - Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting
• 04.21.2025 - Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer
• 04.21.2025 - Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer

Recent Filings

• 05.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.08.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.08.2025 - 8-K Current report
• 05.08.2025 - EX-99.1 EX-99.1
• 04.29.2025 - DEF 14A Other definitive proxy statements
• 04.29.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.29.2025 - ARS Annual Report to Security Holders
• 04.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.11.2025 - 4 Statement of changes in beneficial ownership of securities